

## Clinical Trials (cont'd.)

### HOPON (Open)

A phase III study of hyperbaric oxygen for the prevention of osteoradionecrosis.

### PACIFICO (Open)

Purine-alkylator combination in follicular lymphoma immunochemotherapy for older patients.

### ITEM (Follow-up)

A Phase II, UK based study of **Imatinib** in the treatment of patients with metastatic uveal melanoma.

### SUAVE (Open)

A randomised phase II study of **Sunitinib** versus **Dacarbazine** in the treatment of patients with metastatic uveal melanoma.

### PET-PANC (Open)

Impact of combined modality positron emission tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer.

### INPIC (Open)

The role of cordotomy in the management of mesothelial-related pain in the UK.

The following new studies are currently in set-up: **TITAN**, **IMCAT**, **CLL-210**, **REALISTIC**, **UKLS**, **Dahanca-21**, **NITRO**, **VIP**, **SUAVE** sample collection and **RIALto**.

## Further Information

For more information about current trials running within the Liverpool Cancer Trials Unit, please email:

[lctu@liverpool.ac.uk](mailto:lctu@liverpool.ac.uk)

Or visit the LCTU website:

[www.lctu.org.uk](http://www.lctu.org.uk)

## The LCTU

The Liverpool Cancer Trials Unit works closely with **Cancer Research UK** in the clinical research of new and existing products for the treatment of cancer, easing suffering and improving the quality of life for cancer patients.

The LCTU is recognized for having a positive impact on people's lives, meeting the needs and surpassing external expectations with the services we offer. It offers a dynamic workplace in which people can realise their professional ambitions while being involved in a dedicated team to Clinical Research.

## MANAGEMENT



### Director

Professor John Neoptolemos  
e: [john.neoptolemos@liv.ac.uk](mailto:john.neoptolemos@liv.ac.uk)



### Assistant Director

Miss Paula Ghaneh  
e: [paula@liverpool.ac.uk](mailto:paula@liverpool.ac.uk)



### Operational Director

Dr Seema Chauhan  
e: [chauhans@liverpool.ac.uk](mailto:chauhans@liverpool.ac.uk)



### Deputy Director

Miss Charlotte Rawcliffe  
e: [clr001@liverpool.ac.uk](mailto:clr001@liverpool.ac.uk)



CANCER RESEARCH UK




## About the LCTU

The Cancer Research UK Liverpool Cancer Trials Unit (LCTU) is based within the Faculty of Health and Life Sciences, Department of Molecular and Clinical Cancer Medicine. The LCTU is responsible for conducting large Phase III trials.

The portfolio of clinical trials involves several major tumour areas including Pancreatic, Lung and Head and Neck along with Melanoma, Lymphoma and Haematological Malignancies with plans for expansion into further areas.

The aim of the LCTU is to conduct and provide support for clinical trials undertaken nationally and internationally. The LCTU provides advice and support on all aspects of trial design and management.



The LCTU is established with core funding from Cancer Research UK and is supported by the University of Liverpool and the two major NHS trusts responsible for delivering the bulk of care in the Liverpool City region: the Royal Liverpool University Hospital and Clatterbridge Centre for Oncology. The Director of the LCTU is Professor John P. Neoptolemos.

The LCTU also oversees the (CR-UK/NIHR) Liverpool Experimental Cancer Medicine Centre (LECMC) responsible for Phase I/II trials. Both the LCTU and LECMC are key components of the Cancer Research UK Centre Cancer Research Centre.

## The Cancer Research UK Liverpool Cancer Research Centre

The Cancer Research UK Liverpool Cancer Research Centre formally came into being in July 2009. Core funding provides infrastructure posts to promote integrative cancer research in the University of Liverpool and a funded programme for clinical and non-clinical PhD training posts.

## Clinical Trials

### TeloVac (Open)

A prospective, phase III, controlled, open label, multicentre, randomised clinical trial comparing combination **Gemcitabine** and **Capecitabine** therapy with concurrent and sequential chemo immunotherapy using the telomerase vaccine **GV1001** in locally advanced and metastatic pancreatic cancer.

### ESPAC-4 (Open)

European Study Group for Pancreatic Cancer (ESPAC) - Trial 4. Combination versus single agent adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.

### ESPAC-4T (Open)

Prospective sample collection for ESPAC-4.

### ESPAC-3 (Follow-up)

(ESPAC) - Trial 3(v2). Adjuvant chemotherapies in respectable pancreatic cancer.

### ESPAC-Tplus (Open)

Designed to allow both prospective and retrospective sample collection and analysis in order to enable high quality translational research to be embedded in the ESPAC trials.

### EUROPAC2 (Open)

A multicentre, randomised, phase III, double blind, placebo controlled, parallel group, outpatient study in patients aged 5-65 with hereditary pancreatitis and idiopathic chronic pancreatitis.